Bharat Biotech announces animal trials of its COVID-19 vaccine ‘Covaxin’ successful

Representational image

In a positive development towards the development of COVID-19 vaccine, Hyderabad-based Bharat Biotech has announced that animal trials of its vaccine candidate ‘Covaxin’ have been successful.

Bharat Biotech said the results demonstrated protective efficacy of the vaccine in a live viral challenge model. It said that the data from the study on primates substantiates the immunogenicity of the vaccine candidate.

A two-dose vaccination regimen of inactivated coronavirus vaccine candidates was administered in 20 rhesus macaques (divided into four groups equally).

ALSO READ: COVID-19 | Top 10 global developments this Saturday morning

One group was administered with placebo, while three groups were immunized with 3 different vaccine candidates at 0 and 14 days. All the macaques were exposed to viral challenge 14 days after the 2nd dose.

Results showed protective efficacy, increasing coronavirus specific IgG and neutralizing antibodies, reducing replication of the virus in the nasal cavity, throat, and lung tissues of monkey.

No evidence of pneumonia was observed by histopathological examination in vaccinated groups, unlike the placebo group.

Adverse events were not seen in animals immunized with a two-dose vaccination regimen.

‘COVAXIN’ ANIMAL TRIALS: ALL YOU NEED TO KNOW 

  • A 2-dose vaccination regimen of inactivated SARS-CoV-2 vaccine candidates was administered in 20 rhesus macaques (divided into four groups equally).
  • One group was administered with placebo, while three groups were immunized with 3 different vaccine candidates at 0 and 14 days. All the macaques were exposed to viral challenge 14 days after the 2nd dose.
  • The results showed protective efficacy, increasing SARS-CoV-2 specific IgG and neutralizing antibodies, reducing replication of the virus in the nasal cavity, throat, and lung tissues of monkey.
  • No evidence of pneumonia was observed by histopathological examination in vaccinated groups, unlike the placebo group
  • Adverse events were not seen in animals immunized with a two-dose vaccination regimen.

“We report the two-dose vaccination regimen of inactivated SARS-CoV-2 vaccine candidates found to induce a strong immune response and protection of animals from the infection of SARS-CoV-2,” Bharat Biotech said in its report.

Meanwhile, drug regulator DCGI has directed Pune-based Serum Institute of India (SII) to suspend recruitment in its clinical trials of AstraZeneca’s potential COVID-19 vaccine in the country till further orders.

ALSO READ: AstraZeneca puts COVID-19 vaccine trials on hold after unexpected illness in volunteer

Click here for Latest News updates and viral videos on our AI-powered smart news

For viral videos and Latest trends subscribe to NewsMobile YouTube Channel and Follow us on Instagram

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here